News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
12 February 2026

Dealmakers: Cenk Olcay Seran, ECC

TXF spoke with Cenk Olcay Seran, director of international development at ECC, to outline the EPC contractor's global footprint, from structuring DFI and ECA-backed debt for...

Perspective
23 February 2026

Calmer waters for European offshore?

The political support is definitely there, but offshore wind in the North Sea is producing mixed results. What do the results of the UK auction - and delays to the German...